Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans

Circulation

Volumn 100, Issue 6, 1999, Pages 594-598

  Eriksson, Mats ^a   Carlson, Lars A ^a   Miettinen, Tatu A ^b   Angelin, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Karolinska Hospital ^*

Author keywords

Apolipoproteins; Atherosclerosis; Cholesterol; Lipoproteins; Metabolism

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; PROTEIN PRECURSOR; RECOMBINANT PROAPOLIPOPROTEIN A1; UNCLASSIFIED DRUG;

ADULT; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FECES; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIPOPROTEIN BLOOD LEVEL; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEROID EXCRETION; ULTRACENTRIFUGATION;

EID: 0033543084     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.6.594     Document Type: Article

References (46)

1. Breslow J. Familial disorders of high-density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 1995:2031-2052.
2. Grundy SM. Lipids, nutrition and coronary disease. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996:45-68.
3. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 1996:1981-2030.
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-923.
5. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984;25: 1017-1058.
6. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
7. Tall AR, Breslow JL. Plasma high-density lipoproteins and atherogenesis. In Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996:105-128.
8. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241.
9. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y, Natio M, Ruan YM, Takahashi K, Ohta T, Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1882-1888.
10. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 1991;353:265-267.
11. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein A-I transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
12. Liu AC, Lawn RM, Verstuyft JG, Rubin EM. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein (a) in transgenic mice. J Lipid Res. 1994;35:2263-2267.
13. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B. Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998;97:780-785.
14. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
15. Miller NE, LaVille A, Crook D. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature. 1988; 314:109-111.
16. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
17. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 1996;37:2473-2491.
18. Steinberg D. A docking receptor for HDL cholesterol esters. Science. 1996;271:460-461.
19. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
20. Landschulz KT, Pathak RK, Rigotti A, Krieger M, Hobbs HH. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest. 1996;98: 984-995.
21. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414-417.
22. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-1659.
23. Angelin B. Studies on the regulation of hepatic cholesterol metabolism in humans. Eur J Clin Invest. 1995;25:215-224.
24. Carlson LA. Effect of a single infusion of recombinant human proapolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high-density-lipoprotein cholesterol. Nutr Metab Cardiovasc Dis. 1995;5:85-91.
25. Eriksson M, Berglund L, Rudling M, Henriksson P, Angelin B. Effects of estrogen on low density lipoprotein metabolism in males: short-term and long-term studies during hormonal treatment of prostatic carcinoma. J Clin Invest. 1989;84:802-810.
26. Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglund L, Angelin B. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest. 1991;87:591-596.
27. Davignon J, Simmonds WJ, Ahrens EH Jr. Usefulness of chromic oxide as an internal standard for balance studies in formula-fed patients and for assessment of caloric function. J Clin Invest. 1968;47:127-138.
28. Moguilevski N, Roobol C, Loriau R, Guillaume JP, Jacobs P, Cravandor A, Herzog A, Brouwers L, Scarso A, Gilles P, Holmquist L, Carlson LA, Bollen A. Production of recombinant proapolipoprotein A-I in Escherichia coli: purification and biochemical characterization. DNA. 1989;8: 429-436.
29. Westman JA, Roobol C, Carlson LA, Wülfert E. Efflux of cholesterol from cholesterol laden human monocyte derived macrophages by complexes of apolipoprotein A-I or proapolipoprotein A-I and phosphatidyl-choline. Nutr Metab Cardiovasc Dis. 1995;5:297-305.
30. Eriksson M, Angelin B, Henriksson P, Ericsson S, Vitols S, Berglund L. Metabolism of lipoprotein remnants in humans: studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the LDL receptor. Arterioscler Thromb. 1991;11:827-837.
31. Nemeth A, Myrdal U, Veress B, Rudling M, Berglund L, Angelin B. Studies on lipoprotein metabolism in a family with jejunal chylomicron retention. Eur J Clin Invest. 1995;25:271-280.
32. Tilvis RS, Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr. 1986;43:92-97.
33. Miettinen TA, Koivisto P. Non-cholesterol sterols and bile acid production in hypercholesterolemic patients with ileal by-pass. In: Paumgartner G, Stiehl A, Gerok W, eds. Bile Acids and Cholesterol in Health and Disease. Boston, Mass: MTP Press; 1983:183-187.
34. Miettinen TA, Tilvis RS, Kesäniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990; 1:20-31.
35. Miettinen TA, Ahrens EH Jr, Grundy SM. Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J Lipid Res. 1965;6:411-424.
36. Grundy SM, Ahrens EH Jr, Miettinen TA. Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal bile acids. J Lipid Res. 1965;6:397-410.
37. Miettinen TA. Gas-liquid chromatographic determination of fecal neutral steroids using a capillary column. Clin Chim Acta. 1982;124:245-248.
38. Shepherd J, Packard CJ, Gotto AM Jr, Taunton OD. Comparison of two methods to investigate the metabolism of human apolipoproteins A-I and A-II. J Lipid Res. 1978;19:656-661.
39. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I, and apo A-II fractional catabolic rate in patients with low high-density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 1991; 87:536-544.
40. Schaefer EJ, Zech LA, Jenkins LL, Bronzen TJ, Rubalcaba EA, Lindgren FT, Aamodt RL, Brewer HB. Human apolipoprotein A-I and A-II metabolism. J Lipid Res. 1982;23:850-862.
41. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res. 1996;37: 1776-1785.
42. Hillebrant CG, Nyberg B, Einarsson K, Eriksson M. The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans. Gut. 1997;41:700-704.
43. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
44. Björkhem I, Miettinen TA, Reihnér E, Ewerth S, Angelin B. Correlation between serum levels of some cholesterol precursors and activity of HMG CoA reductase in human liver. J Lipid Res. 1987;28:1137-1143.
45. Kempen HJM, Glantz JFC, Leuven JAG, van der Boon HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29:1149-1155.
46. Goodman DS, Smith FR, Seplowitz AH, Ramakrishnan R, Dell RB. Prediction of parameters of whole body cholesterol metabolism in humans. J Lipid Res. 1980;21:699-713.